Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

MediPD: An Online Mediterranean Diet Program for People Living With Parkinson's Disease (MediPD)

22 oktober 2026 bijgewerkt door: Claire McEvoy, Queen's University, Belfast

Feasibility Of An Online Self-management Mediterranean Diet Program To Improve Dietary Behaviour And Quality Of Life For People Living With Parkinson's Disease: The MediPD Pilot Randomised Controlled Trial

The aim of this pilot study is to assess whether an online Mediterranean diet programme called MediPD is acceptable and practical for people living with Parkinson's disease, and whether it can help them make and maintain changes towards a Mediterranean-style diet.

The study will include 120 adults living in the United Kingdom with Parkinson's disease who have access to an internet-enabled device and currently have low adherence to a Mediterranean-style diet. Participants will be randomly assigned to one of two groups. One group will receive access to the MediPD online programme, which includes short educational videos, personalised dietary information, practical resources, goal-setting tools, and online dietetic support. The other group will continue with their usual care and will receive access to MediPD after completing the final study assessment.

Researchers will compare the groups to see whether MediPD improves adherence to a Mediterranean diet after 24 weeks. The study will also examine dietary intake, non-motor symptoms, quality of life, gastrointestinal symptoms, cognitive function, and how acceptable and practical the programme is to use. Assessments will take place at the start of the study, at 12 weeks, and at 24 weeks.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

120

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Nicola A Ward, PhD, MSci
  • Telefoonnummer: +44(0)7823368444
  • E-mail: medipd@qub.ac.uk

Studie Contact Back-up

  • Naam: Sinead O'Hagan, MSc
  • Telefoonnummer: +44(0)7823368444
  • E-mail: medipd@qub.ac.uk

Studie Locaties

      • Belfast, Verenigd Koninkrijk, BT12 6BA
        • Werving
        • Remote assessments from Centre for Public Health, Queens University Belfast
        • Contact:
          • Nicola Ann Ward, PhD, MSci
          • Telefoonnummer: 07823368444
          • E-mail: medipd@qub.ac.uk
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Self-reported idiopathic Parkinson's disease
  • Age 18 years or older
  • Community-dwelling and resident in the United Kingdom
  • Access to an internet-enabled device and an active email address
  • Mediterranean Diet Score ≤7/13, indicating low adherence to a Mediterranean diet
  • Proficient in English
  • Able to provide informed consent

Exclusion Criteria:

  • Atypical or secondary parkinsonism
  • Living in an institution
  • Self-reported body mass index <18.5 kg/m²
  • High risk of malnutrition, defined as MUST score ≥2
  • Receiving prescribed nutritional support
  • Significant cognitive impairment, defined as T-CogS ≤21
  • Pregnancy
  • Active inflammatory bowel disease
  • Dysphagia requiring a pureed diet
  • Food allergies that would prevent adherence to a Mediterranean-style diet
  • Following a vegan diet that would prevent adherence to the study's Mediterranean-style dietary intervention.
  • Current participation in another interventional trial
  • Participation in an investigational medicinal product trial within the previous 90 days where this may affect study outcomes or participant burden
  • Previous participation in a My Moves Matter dietary programme.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: MediPD Intervention

Participants will receive access to the 12-week MediPD online Mediterranean diet behaviour-change program

MediPD is a 12-week online Mediterranean diet behaviour-change programme for people with Parkinson's disease. It provides personalised educational videos, practical resources, self-monitoring tools, and moderated dietetic support. Participants are encouraged to complete at least one module per week, aiming to adopt and maintain Mediterranean-style dietary changes over 24 weeks.

Geen tussenkomst: Wait-List Control

Participants will continue to receive their usual care. After completing the final 24-week study assessment, participants in the wait-list control group will be offered access to the MediPD online program for 12 weeks.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 24 Weeks
Tijdsspanne: Baseline to 24 weeks

Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.

Baseline to 24 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 12 Weeks
Tijdsspanne: Baseline to 12 weeks

Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet.

Baseline to 12 weeks
Change in self-reported dietary intake using a 24-hour Dietary Recall
Tijdsspanne: Baseline, 12 weeks and 24 weeks.

Dietary intake will be assessed using Intake24, an online 24-hour dietary recall tool. Outcomes will include mean daily intake of energy (kcal/day), foods and macronutrients (g/day and, where appropriate, percentage of energy), and micronutrients (mg or µg/day, as appropriate). Higher values indicate greater intake of food/nutrients.

Baseline, 12 weeks and 24 weeks.
Change in Parkinson's Disease Non-Motor Symptoms using the Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
Tijdsspanne: Baseline, 12 weeks and 24 weeks.

Non-motor symptoms will be assessed using the validated 52-item, rater-administered Movement Disorder Society Non-Motor Rating Scale (MDS-NMS). Total scores range from 0 to 832, with higher scores indicating a greater non-motor symptom burden and a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in reported Gastrointestinal Symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Tijdsspanne: Baseline, 12 weeks and 24 weeks.

Gastrointestinal symptoms will be assessed using the 15-item Gastrointestinal Symptom Rating Scale (GSRS). Items are scored from 1 to 7 and summed to provide a total score ranging from 15 to 105. Higher total scores indicate greater gastrointestinal symptom severity and therefore a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
Tijdsspanne: Baseline, 12 weeks and 24 weeks.

Quality of life will be assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39), which covers eight domains. Each domain score is transformed to a 0-100 scale, and the mean of the eight domain scores provides the PDQ-39 Summary Index. Higher Summary Index scores indicate poorer health-related quality of life and therefore a worse outcome.

Baseline, 12 weeks and 24 weeks.
Change in cognitive function using TestMyBrain cognitive test battery
Tijdsspanne: Baseline, 12 weeks and 24 weeks.

Cognitive function will be assessed using the TestMyBrain cognitive test battery, comprising Verbal Paired Associates, Visual Paired Associates, Backward Digit Span, Digit Symbol Matching, and Trail Making A and B. Each test score will be converted to a z-score and oriented so that higher scores consistently indicate better performance. The z-scores will be summed to provide an overall cognitive composite score with higher scores indicating better cognitive function.

Baseline, 12 weeks and 24 weeks.

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in whole-gut transit time using the Blue Poop Challenge (optional assessment)
Tijdsspanne: Baseline, 12 weeks and 24 weeks.

Consenting participants who opt into this assessment will consume a standardised food-grade blue dye preparation and record the date and time of ingestion and the first appearance of blue colouring in their stool. Whole-gut transit time will be calculated as the elapsed time in hours between ingestion and the first appearance of blue stool. Higher values indicate a longer, slower whole-gut transit time.

Baseline, 12 weeks and 24 weeks.
Intervention acceptability using a study-specific semi-structured qualitative interview
Tijdsspanne: Week 24

Intervention acceptability will be explored through a study-specific semi-structured interview with a purposive sample of approximately 10-15 participants from the MediPD intervention group. Interviews will explore satisfaction and acceptability, relevance and usefulness, engagement, feasibility, platform usability, perceived impact, participant burden, barriers and facilitators, and suggestions for improvement. Interviews will be audio-recorded, transcribed verbatim and analysed qualitatively to identify key themes. This assessment does not generate a numerical score and therefore has no minimum or maximum value.

Week 24

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Claire T McEvoy, PhD, Mphil, RD, Queens University Belfast

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 oktober 2026

Primaire voltooiing (Geschat)

30 augustus 2027

Studie voltooiing (Geschat)

29 februari 2028

Studieregistratiedata

Eerst ingediend

10 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

17 september 2026

Eerst geplaatst (Werkelijk)

24 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

26 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

22 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren